Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BRIACELL THERAP (BCTX : NSDQ)

• Company Description    BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $4.47 Daily Weekly Monthly 20 Day Moving Average: 439,842 shares Shares Outstanding: 15.28 (millions) Market Capitalization: $68.30 (millions) Beta: 1.13 52 Week High: $12.47 52 Week Low: $2.82 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -41.57% -35.97% 12 Week -43.70% -38.92% Year To Date -46.01% -35.80%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3RD FLOOR BELLEVUE CENTRE 235-15TH STR - WEST VANCOUVER,A1 V7T 2X1 CAN ph: 604-921-1810 fax: 604-921-1898 None http://www.briacell.com

• General Corporate Information    Officers William V. Williams - President and Chief Executive Officer Gadi Levin - Chief Financial Officer Charles Louis Wiseman - Founder; Principal Advisor & Member of Scientific Farrah Dean - Mang. of Corp. Devel. Farrah Dean - Mang. of Corp. Devel. Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 10778Y302 SIC: 2834 Fiscal Year Fiscal Year End: July Last Reported Quarter: 01/01/22 Next Expected EPS Date: 07/05/22 Share - Related Items Shares Outstanding: 15.28 Most Recent Split Date: 1.00 (0.00:1) Beta: 1.13 Market Capitalization: $68.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.77 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.49 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 41.46% vs. Previous Quarter: -60.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 04/30/22 - - 01/31/22 - -30.65 10/31/21 - -31.70 ROA 04/30/22 - - 01/31/22 - -29.07 10/31/21 - -28.73 Current Ratio 04/30/22 - - 01/31/22 - 79.86 10/31/21 - 129.74 Quick Ratio 04/30/22 - - 01/31/22 - 79.86 10/31/21 - 129.74 Operating Margin 04/30/22 - - 01/31/22 - - 10/31/21 - - Net Margin 04/30/22 - - 01/31/22 - - 10/31/21 - - Pre-Tax Margin 04/30/22 - - 01/31/22 - - 10/31/21 - - Book Value 04/30/22 - - 01/31/22 - 2.99 10/31/21 - 3.57 Inventory Turnover 04/30/22 - - 01/31/22 - - 10/31/21 - - Debt-to-Equity 04/30/22 - - 01/31/22 - 0.00 10/31/21 - 0.00 Debt-to-Capital 04/30/22 - - 01/31/22 - 0.00 10/31/21 - 0.00

Powered by Zacks Investment Research ©